Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Blood Typing

Blood Typing

Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

Cytomegalovirus Disease

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

The ABO Blood Group

The ABO Blood Group

The ABO blood group system is a critical element of transfusion medicine, essential for determining blood compatibility in transfusions and organ transplants. It is based on specific antigens, or agglutinogens, present on the surface of red blood cells (RBCs) and corresponding antibodies, or agglutinins, in the blood plasma.
Antigens in the ABO Blood Group System
Antigens are substances that can trigger an immune response, leading to the production of antibodies. In the ABO blood group system,...

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

Expert review of clinical pharmacology·2019

Same author

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.

American journal of hematology·2019

Same author

Impact of acquired del(17p) in multiple myeloma.

Blood advances·2019

Same author

Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.

Cancer·2019

Same author

Correction: Waldenström macroglobulinemia treatment algorithm 2018.

Blood cancer journal·2019

Same author

The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.

Bone marrow transplantation·2019

Search research articles

Related Experiment Video

Updated: May 10, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Cold agglutinin disease.

Paul L Swiecicki¹, Livia T Hegerova, Morie A Gertz

¹Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.

|June 13, 2013

Summary

This summary is machine-generated.

Cold agglutinin disease (CAD) is a rare autoimmune disorder. Early diagnosis and treatment, including rituximab, significantly improve patient survival and outcomes.

More Related Videos

Particle Agglutination Method for Poliovirus Identification

Particle Agglutination Method for Poliovirus Identification

Published on: April 20, 2011

Related Experiment Videos

Last Updated: May 10, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Particle Agglutination Method for Poliovirus Identification

Particle Agglutination Method for Poliovirus Identification

Published on: April 20, 2011

Area of Science:

Hematology
Immunology
Rare Diseases

Background:

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia subtype, affecting 15% of patients.
Understanding CAD's clinical features, prognosis, and management is crucial for improving patient outcomes.
Limited data exists on the long-term institutional experience with CAD diagnosis and treatment.

Purpose of the Study:

To review the literature on cold agglutinin disease.
To describe the institutional experience with CAD diagnosis and treatment.
To identify strategies for improving diagnostic accuracy and therapeutic efficacy.

Main Methods:

Retrospective analysis of 89 patients with CAD from 1970-2012.
Literature review of clinical features, prognosis, and management.
Evaluation of treatment responses, focusing on rituximab.

Main Results:

Median age at diagnosis was 72 years; median survival was 10.6 years.
Acrocyanosis was the most common symptom (44%); 78% had an underlying hematologic disorder.
Rituximab showed the longest response duration (24 months) and lowest retreatment rate (55%).

Conclusions:

Early diagnostic evaluation and prompt treatment are vital for improving outcomes in cold agglutinin disease.
Rituximab demonstrates significant efficacy in managing CAD.
Further research into optimal CAD management strategies is warranted.